The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Sanofi (NASDAQ:SNY) said on Thursday its multiple myeloma drug Sarclisa (isatuximab) met the primary endpoints of a late-stage trial. The drug is currently indicated for use in a combination ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

with an initial rollout expected for phase 3 tests of Sanofi’s multiple sclerosis meds. Here’s how the tool is designed: ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas, as well as gastrointestinal and lung cancers. Sanofi and Orano Med are members of the Paris ...

Sanofi is deepening its commitment to targeted ... including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas. The scope of the research will also ...

Its key products include anti-inflammation drug Stelara, multiple myeloma and light chain amyloidosis ... which closed at $324.62 on Oct. 14. Sanofi is a French pharmaceutical company that ...

including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas, as well as gastrointestinal and lung cancers. Sanofi and Orano Med are members of the Paris ...